NYSEARCA:BBC Virtus LifeSci Biotech Clinical Trials ETF (BBC) Price, Holdings, & News $22.87 -0.05 (-0.22%) As of 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsRatingsShort InterestBuy This Stock About Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BBC alerts:Sign Up Key Stats Today's Range$22.81▼$23.5150-Day Range$19.19▼$23.0852-Week Range$13.42▼$31.65Volume17,208 shsAverage Volume44,602 shsMarket Capitalization$16.01 millionAssets Under Management$16.11 millionDividend Yield1.01%Net Expense Ratio0.79%Aggregate RatingModerate Buy ETF Overview The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus. Read More Virtus LifeSci Biotech Clinical Trials ETF ExpensesTypeBBCHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.79%0.56%0.56%0.51%0.53%Other Expenses0.00%0.47%0.56%0.59%0.56%Total Expense0.79%0.75%0.76%0.74%0.73%Fee Waiver0.00%-0.67%-0.66%-0.71%-0.63%Net Expense0.79%0.60%0.63%0.58%0.60% Receive BBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virtus LifeSci Biotech Clinical Trials ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBC ETF News HeadlinesBBC Virtus LifeSci Biotech Clinical Trials ETFMay 23, 2025 | seekingalpha.comFDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To WatchAugust 19, 2024 | benzinga.comWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.August 28 at 2:00 AM | SmartAsset (Ad)Tech ETFs on the Rise After Four Weeks in Deep RedAugust 19, 2024 | theglobeandmail.comVirtus Lifesci Biotech Products Etf Share ChatJuly 20, 2024 | lse.co.ukVirtus Lifesci Biotech Clinical Trials Etf Share ChatJuly 20, 2024 | lse.co.ukSee More Headlines BBC ETF - Frequently Asked Questions How have BBC shares performed this year? Virtus LifeSci Biotech Clinical Trials ETF's stock was trading at $23.94 at the beginning of the year. Since then, BBC stock has decreased by 4.5% and is now trading at $22.87. How do I buy shares of Virtus LifeSci Biotech Clinical Trials ETF? Shares of BBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Virtus LifeSci Biotech Clinical Trials ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Virtus LifeSci Biotech Clinical Trials ETF investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), Meta Platforms (META), e.l.f. Beauty (ELF) and GE Aerospace (GE). Fund Details IssuerVirtus Fund NameVirtus LifeSci Biotech Clinical Trials ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:BBC Inception Date12/16/2014 Fund ManagerMatthew B. Brown, Seth Kadushin WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkLifeSci Biotechnology Clinical Trials Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings119 Fund Statistics Assets Under Management$16.11 million Average Daily Volume$20.16 thousand Discount/Premium-0.10% Administrator, Advisor and Custodian AdministratorVirtus ETF Solutions, LLC AdvisorVirtus ETF Advisers, LLC CustodianThe Bank of New York Mellon Corporation DistributorETF Distributors LLC Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume235 Put Options1 Call Options235 Short Interest17,900 shs Miscellaneous Outstanding Shares700,000Beta1.08 Creation Unit50,000 Creation Fee$500.00 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report Top 10 BBC HoldingsCelcuity (NASDAQ:CELC)Holding Weight: 3.07%Liquidia Technologies (NASDAQ:LQDA)Holding Weight: 1.47%Prothena (NASDAQ:PRTA)Holding Weight: 1.32%Terns Pharmaceuticals (NASDAQ:TERN)Holding Weight: 1.31%Xeris Biopharma (NASDAQ:XERS)Holding Weight: 1.31%Cogent Biosciences (NASDAQ:COGT)Holding Weight: 1.28%Stoke Therapeutics (NASDAQ:STOK)Holding Weight: 1.23%Nuvation Bio (NYSE:NUVB)Holding Weight: 1.17%Upstream Bio (NASDAQ:UPB)Holding Weight: 1.15%Centessa Pharmaceuticals (NASDAQ:CNTA)Holding Weight: 1.13%Full Holdings DetailsBBC Sector ExposureBBC Industry Exposure This page (NYSEARCA:BBC) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Clinical Trials ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Virtus LifeSci Biotech Clinical Trials ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access